Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $68.21 USD
Change Today -0.30 / -0.44%
Volume 6.2M
ABBV On Other Exchanges
Symbol
Exchange
New York
EN Paris
Mexico
Frankfurt
As of 8:04 PM 07/2/15 All times are local (Market data is delayed by at least 15 minutes).

abbvie inc (ABBV) Snapshot

Open
$68.68
Previous Close
$68.51
Day High
$68.90
Day Low
$67.79
52 Week High
12/8/14 - $70.76
52 Week Low
08/6/14 - $51.37
Market Cap
119.4B
Average Volume 10 Days
9.2M
EPS TTM
$3.32
Shares Outstanding
1.8B
EX-Date
07/13/15
P/E TM
20.6x
Dividend
$2.04
Dividend Yield
2.70%
Current Stock Chart for ABBVIE INC (ABBV)

abbvie inc (ABBV) Details

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company’s products include HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; VIEKIRA PAK, an all-oral, short-course, interferon-free therapy, with or without ribavirin, for adult patients with genotype 1 chronic hepatitis, including those with compensated cirrhosis; Kaletra, an anti-HIV-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in people with HIV-1; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1 infection; and Synagis to prevent respiratory syncytial virus infection in high risk infants. It also provides AndroGel, a testosterone replacement therapy for males diagnosed with symptomatic low testosterone; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron, a product for the palliative treatment of prostate cancer, and the treatment of endometriosis and central precocious puberty, as well as for the preoperative treatment of patients with anemia. In addition, the company offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson’s disease; Sevoflurane, an anesthesia product for human use; TriCor, Trilipix, Niaspan, Simcor, and Advicor to treat metabolic conditions characterized by high cholesterol and/or high triglycerides; and Zemplar to treat secondary hyperparathyroidism. It sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. The company has strategic collaboration with Calico Life Sciences LLC, Infinity Pharmaceuticals, Inc., Ablynx NV, Galapagos NV, Alvine Pharmaceuticals, Inc., and Action Pharma A/S. AbbVie Inc. was incorporated in 2012 and is based in North Chicago, Illinois.

26,000 Employees
Last Reported Date: 05/8/15
Founded in 2012

abbvie inc (ABBV) Top Compensated Officers

Chairman, Chief Executive Officer and Chairma...
Total Annual Compensation: $1.6M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $923.7K
Chief Scientific Officer and Executive Vice P...
Total Annual Compensation: $1.5M
Executive Vice President of Commercial Operat...
Total Annual Compensation: $844.5K
Executive Vice President of Business Developm...
Total Annual Compensation: $957.6K
Compensation as of Fiscal Year 2014.

abbvie inc (ABBV) Key Developments

AbbVie's Humira (Adalimumab) Receives Positive CHMP Opinion to Treat Adult Patients with Active Moderate to Severe Hidradenitis Suppurativa

AbbVie announced that the European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion for HUMIRA (adalimumab) for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adult patients with an inadequate response to conventional systemic hidradenitis suppurativa (HS) therapy. HS is a painful, chronic inflammatory skin disease estimated to impact approximately 1% of the adult population worldwide. If granted marketing authorization by the European Commission, HUMIRA will become the first and only medication approved for HS. The positive opinion is based on the results of two pivotal Phase 3 studies, PIONEER I and PIONEER II. These studies demonstrated that moderate to severe HS patients treated with HUMIRA 40 mg weekly starting at Week 4 following 160 mg at Week 0 and 80 mg at Week 2 achieved a significantly greater response versus those on placebo at 12 weeks using the Hidradenitis Suppurativa Clinical Response (HiSCR) measure. This is defined as at least 50% reduction from baseline in total abscess and inflammatory nodule (AN) count with no increase for either abscess or draining fistula count. Additionally, at Week 12, a significantly higher proportion of HUMIRA treated patients in PIONEER II experienced a clinically relevant decrease in HS-related skin pain (as measured by >30% Reduction in Skin Pain) compared to those on placebo. No new safety signals were identified in these trials. The review of the HS application is being conducted under the centralized licensing procedure. If approved, the authorization will be valid in all 28 member states of the European Union, as well as Iceland, Liechtenstein and Norway.

AbbVie Opts Out of Co-Development Agreement with Biotest

AbbVie has decided to opt out of a co-development agreement with Biotest for the compound Tregalizumab (BT-061. AbbVie's withdrawal from the agreement, first signed in 2011, follows an announcement in April that a Phase IIb study of Tregalizumab in moderate to severe rheumatoid arthritis did not meet its primary endpoint.

AbbVie Announces New Phase 3b Results in Genotype 1b Chronic Hepatitis C Patients with Compensated Liver Cirrhosis

AbbVie announced TURQUOISE-III study results demonstrating 100% (n=60/60) sustained virologic response at 12 weeks post-treatment (SVR12) in genotype 1b (GT1b) chronic hepatitis C virus (HCV) infected adult patients with compensated liver cirrhosis. Patients received 12 weeks of VIEKIRAX (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA (dasabuvir tablets) without ribavirin (RBV). These new results from AbbVie's Phase 3b study will be presented at the 15th Annual International Symposium on Viral Hepatitis and Liver Diseases in Berlin, Germany. Approximately 160 million people worldwide are infected with HCV. Genotype 1 is the most common type of HCV genotype, accounting for 60% of cases worldwide and in Europe, the most prevalent genotype is 1b (47%). Over time, chronic HCV may lead to liver complications, including compensated cirrhosis, in about 10%-20% of people infected. Patients in TURQUOISE-III were either treatment-naïve or treatment-experienced (failed previous therapy with pegylated interferon and RBV). No patients discontinued treatment due to adverse events. The most commonly reported adverse events (>10%) were fatigue (22%), diarrhea (20%) and headache (18%).

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ABBV:US $68.21 USD -0.30

ABBV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Amgen Inc $153.26 USD -1.73
Bristol-Myers Squibb Co $67.48 USD -0.19
Eli Lilly & Co $86.14 USD +1.29
Medtronic PLC $73.81 USD -0.27
Novo Nordisk A/S kr368.70 DKK -2.20
View Industry Companies
 

Industry Analysis

ABBV

Industry Average

Valuation ABBV Industry Range
Price/Earnings 59.9x
Price/Sales 5.2x
Price/Book 77.7x
Price/Cash Flow 58.9x
TEV/Sales 4.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ABBVIE INC, please visit www.abbvie.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.